Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985

Autor: C. Marco Timmers, Tijl Huijbregts, Ronald Christiaan Elgersma, Franciscus M. H. de Groot, GF Verheijden, Ruud Coumans, Patrick Henry Beusker, Jacques M. Lemmens, David F. Egging, Diels van den Dobbelsteen, Miranda M.C. van der Lee, Ruud Ubink, Wim H. A. Dokter, Wiro Michaël Petrus Bernardus Menge, Henri Johannes Spijker, John Joosten

Publikováno v: Molecular Pharmaceutics. 12:1813-1835

Antibody-drug conjugates (ADCs) that are currently on the market or in clinical trials are predominantly based on two drug classes: auristatins and maytansinoids. Both are tubulin binders and block the cell in its progression through mitosis. We set

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d112fc7f8b9f7d0584c7c81aa6b00e7
https://doi.org/10.1021/mp500781a

Selection of Self-reactive peptides within human aggrecan by use of HLA-DRB1*0401 peptide binding motif

Autor: Amh Boots, I. Joosten, R. Schöningh, Dirk Elewaut, E Bos, C. J. Van Staveren, Eric Veys, GF Verheijden, Awm Rijnders, F De Keyser

Publikováno v: Journal of Autoimmunity, 10, pp. 569-578
Journal of Autoimmunity, 10(6), 569-578. ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
Journal of Autoimmunity, 10, 569-578

The pathogenesis of joint destruction in rheumatoid arthritis remains ill-defined. Joint destruction is thought to be the result of tissue damage mediated by T cells. The mere presence of articular cartilage appears responsible for sustaining chronic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec010ac0401e303e5ae822e37676f6df
https://hdl.handle.net/2066/24866

Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis

Autor: André M. M. Miltenburg, Dirk Elewaut, Dominique Baeten, Annemieke M. H. Boots, E M Veys, G. Verbruggen, GF Verheijden, F De Keyser, Peter G. A. Steenbakkers, Awm Rijnders, E Bos

Publikováno v: Arthritis and rheumatism, 43(6), 1233-1243. John Wiley and Sons Inc.
ARTHRITIS AND RHEUMATISM, 43(6), 1233-1243. John Wiley and Sons Inc.

Objective. To investigate the expression of human cartilage (HC) gp-39, a possible autoantigen in rheumatoid arthritis (RA), in peripheral brood and synovium, to characterize its cellular source, and to analyze correlations with clinical features, Me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50b785a068030f2fd918e5a17845f733
https://pure.amc.nl/en/publications/human-cartilage-gp39cd16-monocytes-in-peripheral-blood-and-synovium-correlation-with-joint-destruction-in-rheumatoid-arthritis(8057674f-cb2a-4ac9-82e2-6d8861bbec91).html

Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263–275) epitope: an MHC anchor variant peptide for immune modulation

Autor: Cindy van Doorn, Cornelis Marius Timmers, Annemieke M. H. Boots, Henk A. J. M. Hubers, Catharina J. van Staveren, Rachel Stenger, Bernice M. Westrek-Esselink, GF Verheijden, Leontien den Hoed-van Zandbrink, E Bos, Marie Jose C. van Lierop, Milou Kouwijzer

Publikováno v: Arthritis Research & Therapy

We sought to identify an altered peptide ligand (APL) based on the endogenously expressed synovial auto-epitope of human cartilage glycoprotein-39 (HC gp-39) for modulation of cognate, HLA-DR4-restricted T cells. For this purpose we employed a panel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dfa27d8398782075111bfab85916e99
https://doi.org/10.1186/ar2269

A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.

Autor: Rouwendal GJ; a Synthon Biopharmaceuticals B.V. ; Nijmegen ; The Netherlands., van der Lee MM; a Synthon Biopharmaceuticals B.V. ; Nijmegen ; The Netherlands., Meyer S; b Laboratory for Translational Immunology; University Medical Center Utrecht ; Utrecht ; The Netherlands., Reiding KR; c Center for Proteomics and Metabolomics; Leiden University Medical Center ; Leiden ; The Netherlands., Schouten J; a Synthon Biopharmaceuticals B.V. ; Nijmegen ; The Netherlands., de Roo G; a Synthon Biopharmaceuticals B.V. ; Nijmegen ; The Netherlands., Egging DF; a Synthon Biopharmaceuticals B.V. ; Nijmegen ; The Netherlands., Leusen JH; b Laboratory for Translational Immunology; University Medical Center Utrecht ; Utrecht ; The Netherlands., Boross P; b Laboratory for Translational Immunology; University Medical Center Utrecht ; Utrecht ; The Netherlands., Wuhrer M; c Center for Proteomics and Metabolomics; Leiden University Medical Center ; Leiden ; The Netherlands.; d Division of BioAnalytical Chemistry; VU University Amsterdam ; Amsterdam , The Netherlands., Verheijden GF; a Synthon Biopharmaceuticals B.V. ; Nijmegen ; The Netherlands., Dokter WH; a Synthon Biopharmaceuticals B.V. ; Nijmegen ; The Netherlands., Timmers M; a Synthon Biopharmaceuticals B.V. ; Nijmegen ; The Netherlands., Ubink R; a Synthon Biopharmaceuticals B.V. ; Nijmegen ; The Netherlands.

Publikováno v: MAbs [MAbs] 2016; Vol. 8 (1), pp. 74-86. Date of Electronic Publication: 2015 Oct 06.